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Introduction
Ginkgolide A, ginkgolide B, ginkgolide C, and ginkgolide J are a group of structurallyrelated terpene trilactones (Fig. 1) . They represent a subset of the bioactive chemical constituents in Ginkgo biloba extract (van Beek and Montoro, 2009) . As shown in studies with these ginkgolides as single chemical entities, differences exist in their biological properties, despite being highly similar in their chemical structures. For example, ginkgolide B and ginkgolide C are more efficacious than ginkgolide A and ginkgolide J in antagonizing glycinegated chloride channel (Ivic et al., 2003) . Ginkgolide B (Xiao et al., 2010) and ginkgolide J (Vitolo et al., 2009 ) also inhibit β -amyloid-induced cell death in rodent hippocampal neurons.
Other actions of ginkgolide B include antagonism of platelet-activating factor receptor and antiapoptotic, anti-inflammatory, antioxidant, and anti-proliferative activities (Xia and Fang, 2007) .
As part of the goal to develop ginkgolides as drug candidates, efforts have been made to synthesize various analogues of ginkgolides and elucidate their structure-activity relationships (Jensen et al., 2010) .
Pregnane X receptor (PXR; NR1I2), constitutive androstane receptor (CAR; NR1I3; originally known as MB67), and glucocorticoid receptor (GR; NR3C1) are members of the superfamily of nuclear receptors (Germain et al., 2006) . These three receptors play important roles in maintaining homeostasis and essential physiological functions. For example, PXR and CAR are involved in glucose homeostasis, bile acid homeostasis, lipid metabolism, and the biotransformation and transport of drugs and endogenous chemicals (Kakizaki et al., 2008) , whereas GR plays a role in growth, anti-inflammatory and immune response (Nicolaides et al., 2010) . Previous studies have shown that GR regulates the expression of PXR and CAR (Pascussi et al., 2001 ), which in turn may modulate the actions of these two receptors. Due to This article has not been copyedited and formatted. The final version may differ from this version. In cell-based reporter gene assays, ginkgolide A, ginkgolide B, and ginkgolide C (to a small extent), but not ginkgolide J, were shown to activate human PXR (hPXR), as assessed with a reporter plasmid containing the ABCB1 promoter (Satsu et al., 2008) . Ginkgolide A and ginkgolide B have also been shown to activate hPXR in a study that used a CYP2B6 reporter containing the phenobarbital-responsive enhancer module and the distal xenobiotic-responsive enhancer module (Li et al., 2009) . Our previous studies showed that ginkgolide A, but not ginkgolide B, ginkgolide C, or ginkgolide J, contributed to hPXR activation by G. biloba extract (Lau et al., 2010) , whereas none of these chemicals was responsible for the activation of the wild-type form of human CAR (hCAR-WT) or one of its splice variants (hCAR-SV23) by the extract (Lau et al., 2011) . However, it is not known how the ginkgolides activate hPXR and whether the ginkgolides differentially affect the function of hPXR, human GR (hGR), and human CAR (hCAR). Given that this class of ginkgolides is structurally similar, they are potentially useful chemical tools to study the structural determinants of nuclear receptor function.
In the present study, we compared the effects of individual ginkgolides (i.e. ginkgolide A, ginkgolide B, ginkgolide C, and ginkgolide J) as single chemical entities on the function of hPXR, hGR, and hCAR. Recently, several splice variants of hCAR (hCAR-SV23, hCAR-SV24, and hCAR-SV25) have been shown to be differentially activated by drugs and other chemicals (Lau et al., 2011) . Therefore, we determined whether the ginkgolides affect the activity of these hCAR splice variants. Given the pronounced species differences in PXR activation , we conducted detailed dose-response experiments to compare the effect of the ginkgolides on the activity of hPXR and rat PXR (rPXR). Additional mechanistic experiments This article has not been copyedited and formatted. The final version may differ from this version. chain reaction (PCR) analyses were described previously (Lau et al., 2010) .
Plasmids. pCMV6-XL4-hPXR, pCMV6-AC-rPXR, pCMV6-XL5-hGR, pCMV6-XL4-hCAR-WT, pCMV6-neo-hCAR-SV23, pCMV6-XL4-hCAR-SV24, pCMV6-XL5-hCAR-SV25, pCMV6-XL4, pCMV6-AC, pCMV6-XL5, and pCMV6-neo were purchased from OriGene
Technologies (Rockville, MD). pGRE-luc reporter and pFR-luc reporter (contains five tandem repeats of yeast GAL4 binding sites) were bought from Agilent Technologies (Santa Clara, CA).
This article has not been copyedited and formatted. The final version may differ from this version. (Goodwin et al., 1999) and pGL3-basic-CYP2B6-PBREM/XREM-luc reporter (Wang et al., 2003) were constructed as described previously. The pVP16 and pM vectors were provided in the Matchmaker Mammalian Two-Hybrid Assay Kit (Clontech Laboratories, Inc., Mountain View, CA). pVP16-hPXR-LBD and pM-hSRC1-RID were constructed as described previously (Lau et al., 2010) . To construct the pM-hPXR-LBD plasmid, the ligand-binding domain of hPXR (Met-107 to Ser-434) was amplified from pCMV6-XL4-hPXR and inserted into the pM vector (contains the yeast GAL4
DNA-binding domain).
Contrary to what was stated in a previous article (Synold et al., 2001) , hPXR (NP_003880) has 434 amino acids, as indicated in the NCBI Reference Sequence
Database. Methionine is the amino acid at position 107, whereas lysine is at position 108. The constructed plasmids were sequenced by the Nucleic Acid Protein Service Unit at the University of British Columbia (Vancouver, BC, Canada), and the identity of the plasmids was confirmed by comparing their sequence with published sequence.
Cell Culture. LS180 human colon adenocarcinoma cells and HepG2 human hepatocellular carcinoma cells were purchased from American Type Culture Collection (Manassas, VA). LS180 cells (Yeung et al., 2008) and HepG2 cells (Lau et al., 2010) were cultured as described previously.
Treatment of LS180 Cells. Cultured LS180 cells were seeded onto 6-well plates at a cell density of 200,000 cells per well. At 72 h after plating, cells were treated with DMSO (0.1% v/v; vehicle) , ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J, or rifampicin (positive control) (Kolars et al., 1992) , at the concentrations indicated in the figure legend. The chemicalcontaining culture medium was replaced every 24 h for a period of 72 h. total cDNA were performed as described previously (Chang et al., 2006) .
PCR Primers.
The sequences of primers for amplification of CYP3A4 cDNA were 5′-CCT-TAC-ACA-TAC-ACA-CCC-TTT-GGA-AGT-3′ (forward) and 5′-AGC-TCA-ATG-CAT-GTA-CAG-AAT-CCC-CGG-TTA-3′ (reverse) (Schuetz et al., 1996) and for amplification of human hypoxanthine phosphoribosyltransferase 1 (hHPRT) cDNA were 5′-GAA-GAG-CTA-TTG-TAA-TGA-CC-3′ (forward) and 5′-GCG-ACC-TTG-ACC-ATC-TTT-G-3′ (reverse) (Qiu et al., 2007) . The primers were synthesized by Integrated DNA Technologies (Coralville, IA), and their specificity was verified by sequencing the purified amplicons (University of British Columbia Nucleic Acid Protein Service Unit, Vancouver, BC, Canada).
Real-Time PCR Analysis. Amplification of cDNA was performed using LightCycler (Roche Diagnostics). CYP3A4 and hHPRT cDNAs were amplified using PCR conditions described previously (Lau et al., 2010) . A calibration curve (cross point versus log cDNA copies) was constructed using known amounts of purified CYP3A4 or hHPRT cDNA, which was amplified from human liver QUICK-Clone cDNA (Clontech Laboratories, Inc., Mountain View, CA) and quantified as described previously (Chang et al., 2006) .
Transient Transfection and Reporter Gene Assays. Cultured HepG2 cells were seeded onto 24-well microplate at a density of 100,000 cells per well (in 0.5 ml culture medium).
At 24 h after plating, cells were transfected with 20 μ l of a transfection master mix containing , or PCN (10 µM; negative control for hPXR and positive control for rPXR) for 24 h at the concentrations indicated in the figure legend. At the end of the treatment period, transfected HepG2 cells were lysed for the determination of firefly luciferase and R. reniformis luciferase activities using a Dual-Luciferase
Reporter Assay System (Promega Corporation). Luminescence was measured using a GloMax 96 microplate luminometer (Promega Corporation). Luciferase activity was expressed as a normalized ratio of firefly luciferase to R. reniformis luciferase activity. Background luciferase activity was determined in HepG2 cells transfected with an empty vector (pCMV6-XL4 or pCMV6-AC), and the value was subtracted from each of the normalized luciferase activity. Fold increase was calculated by dividing the net luciferase activity of the treatment group by that of the vehicle-treated control group. Each independent experiment was performed in triplicate, and a total of four independent experiments were conducted.
hGR-dependent reporter gene assay was determined in HepG2 cells in the same manner as that described for the hPXR-dependent reporter gene assays, except that: a) pCMV6-XL5- 11 µM) was used as positive control for hGR (Pascussi et al., 2001) ; and e) rifampicin (10 µM) was used as a negative control for hGR (Herr et al., 2000) .
hCAR-WT-, hCAR-SV23-, hCAR-SV24-, and hCAR-SV25-dependent reporter gene assays were performed in HepG2 cells, as described previously (Lau et al., 2011) . (positive control for hPXR) , SR12813 (positive control for hPXR) , sodium phenobarbital, or PCN (negative control for hPXR) for 24
h at the concentration indicated in the figure legend.
Competitive Ligand-Binding Assay. A LanthaScreen TR-FRET PXR Competitive
Binding Assay (Invitrogen, Inc.) was conducted according to the manufacturer's protocol as detailed previously (Lau et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. FuGENE 6 transfection reagent as described previously (Lau et al., 2010) . At 24 h after transfection, culture medium containing the transfection mixture was removed and cells were treated with 0.5 ml of fresh culture medium containing DMSO (0.1% v/v; vehicle), ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J, rifampicin (positive control) , SR12813 (positive control) , or PCN (negative control) for 24 h at the concentration indicated in the figure legend. Phenobarbital was included for comparative purposes. Luciferase activity was measured and normalized as described under containing 20 mM EDTA (0.5 ml per well). The LDH assay was performed using the Cytotoxicity Detection Kit, as described previously (Lau et al., 2010 Molecular Docking. There are nine X-ray crystallography structures of hPXR-ligand complexes in the RCSB Protein Data Bank. Three criteria, (1) resolution ≤ 2.5 Å, (2) R value ≤ resolution/10, and (3) difference between R-value and R-free ≤ 0.05, were used to identify structures that were of sufficiently good quality for docking studies. The R-value is a measure of the degree of fit between the structure and the crystallographic data. R-free is calculated using the same method as R-value, except that it is based on data that have not been used to derive the structure. The difference between R-value and R-free shows the degree of over-fitting for the structure (Kleywegt and Jones, 1997) . There was only one structure (PDB ID: 1M13) that met these criteria, and its quality was confirmed in a study comparing five different hPXR structures (Ekins et al., 2009 ).
Molecular Operating Environment (MOE) 2010.10 (Chemical Computing Group, Inc., Montreal, QC, Canada) was used for docking the individual ginkgolides, rifampicin, SR12813, and PCN to the 1M13 structure. 1M13 was first processed by removing bound ligand and water molecules. Hydrogen atoms were then added and ionization states were assigned using the Protonate3D function in MOE. The active site was defined using residues known to line the site.
These residues consist of 17 hydrophobic residues , five polar residues , and four charged residues (Glu-321, His-327, His-407, and Arg-410) (Liu et al., 2011) . cells (Satsu et al., 2008) , which was reported to be an useful model for studying CYP3A4
induction (Gupta et al., 2008) . In agreement with a previous study (Satsu et al., 2008) , ginkgolide A (60 µM) and ginkgolide B (60 µM) increased CYP3A4 mRNA expression, whereas ginkgolide C (60 µM) had no effect (data not shown). In the same experiment, our novel finding indicates a lack of an effect by ginkgolide J (60 µM). Rifampicin (10 µM), which is a positive control for the induction of CYP3A4 (Kolars et al., 1992) , increased CYP3A4 mRNA level by 15-fold.
Comparative Effect of Individual Ginkgolides on the Activity of hPXR, hGR, and hCAR in Transfected HepG2 Cells. hPXR (Lehmann et al., 1998) , hGR (Pascussi et al., 2001) , and hCAR (Goodwin et al., 2002) regulate CYP3A4 expression. Therefore, we compared the effect of the four structurally-related ginkgolides on hPXR, hGR, and hCAR activities. As shown in Fig. 2A , ginkgolide A (100 µM), ginkgolide B (100 µM), and ginkgolide C (100 µM) increased hPXR activity by 11-, 15-, and 4-fold, respectively, whereas ginkgolide J (100 µM) had no effect. Control analysis indicated that rifampicin (10 µM; positive control) activated hPXR by 14-fold and PCN (10 µM; negative control) had no effect. Unlike hPXR, hGR (Fig. 2B ) and hCAR-WT (Fig. 2C ) activities were not increased by any of the four individual ginkgolides. Dexamethasone (0.1 µM; positive control) (Pascussi et al., 2001 ) increased hGR activity by 10-fold (Fig. 2B ) and CITCO (10 µM; positive control) (Maglich et al., 2003) increased hCAR-WT activity by 4-fold (Fig. 2C) , whereas rifampicin (10 This article has not been copyedited and formatted. The final version may differ from this version. (Herr et al., 2000) had no effect on hGR (Fig. 2B) and TCPOBOP (0.25 µM; negative control) had no effect on hCAR-WT (Fig. 2C ).
Given that hCAR splice variants are differentially activated by drugs and other chemicals (Lau et al., 2011) , we determined the effect of the ginkgolides on the activity of hCAR-SV23, hCAR-SV24, and hCAR-SV25 using reporter gene assays conducted on HepG2 cells. As shown in Fig. 2D-F B, ginkgolide C, or ginkgolide J. As shown in Fig. 3A , ginkgolide A, at 0.1-3 µM, had no effect on hPXR activity, whereas at 10, 30, and 60 µM, it increased the activity in a log-linear manner by 5-, 9-, and 11-fold, respectively. The maximum effect was achieved with 60 µM ginkgolide A. The EC 50 and E max values of hPXR activation by ginkgolide A were 16 ± 1 µM and 12 ± 1-fold, respectively. Ginkgolide B, at 0.1-1 µM, had no effect on hPXR activity, whereas at 3, 10, This article has not been copyedited and formatted. The final version may differ from this version. 17 30, 60, and 100 µM, it increased the activity in a log-linear manner by 3-, 5-, 11-, 14, and 15-fold, respectively. Ginkgolide C, at 0.1-30 µM, had no effect on hPXR activity, whereas at 60 and 100 µM, it increased the activity by 3-and 4-fold, respectively. In contrast to the other ginkgolides, ginkgolide J at each of the concentrations (0.1 to 100 µM) investigated had no effect.
By comparison, rifampicin (positive control) , at 1, 3, 10, and 30 µM, increased hPXR activity by 11-, 14-, 11-, and 12-fold, respectively. Its EC 50 value was 0.4 ± 0.1 µM and its E max value was 12 ± 2-fold, which were consistent with literature values (Chang, 2009 ).
To determine whether the ginkgolides activate rPXR, a concentration-response experiment was conducted on HepG2 cells transfected with rPXR. As shown in Fig. 3B , ginkgolide A, at 0.1-3 µM, had no effect on rPXR activity, whereas at 10, 30, and 60 µM, it increased the activity in a log-linear manner by 4-, 8-, and 9-fold, respectively. The maximum effect was achieved with 60 µM ginkgolide A. The EC 50 and E max values of rPXR activation by ginkgolide A were 12 ± 1 µM and 9 ± 1-fold, respectively. Ginkgolide B, at 0.1-3 µM, had no effect on rPXR activity, whereas at 10, 30, 60, and 100 µM, it increased the activity in a loglinear manner by 3-, 6-, 7-, and 8-fold, respectively. Ginkgolide C, at 0.1-10 µM, had no effect on rPXR activity, whereas at 30, 60, and 100 µM, it increased the activity by 2-, 2-, and 3-fold, respectively. In contrast to the other ginkgolides, ginkgolide J at all concentrations (0.1 to 100 µM) had no effect. By comparison, PCN (positive control) , at 1, 3, 10, and 30 µM, increased rPXR activity by 9-, 15-, 16-, and 17-fold, respectively. Its EC 50 value was 1.0 ± 0.2 µM and its E max value was 17 ± 2-fold, which were consistent with literature values (Chang, 2009 Fig. 4 , ginkgolide A (100 µM) and ginkgolide B (100 µM) increased the luciferase activity by 5-and 8-fold, respectively, whereas ginkgolide C (100 µM) and ginkgolide J (100 µM) had no effect. Analyses with positive controls indicated that phenobarbital (1000 µM) , SR12813 (10 µM) , and rifampicin (10 µM) increased the reporter activity by 9-, 10-, and 11-fold, respectively. As expected, PCN (10 µM; negative control) had no effect. None of the treatment groups affected the activity in cells transfected with the pM empty vector. 60 and 50%, respectively, whereas ginkgolide C (1000 µM) and ginkgolide J (1000 µM) had no effect. By comparison, phenobarbital (1000 µM) and SR12813 (10 µM), which are known PXR ligands , decreased the emission ratio by 42% and 92%, respectively. PCN (10 µM), which is a negative control , yielded the expected result. We also 19 effect on the emission ratio, but at 1000 µM, it decreased the ratio by 54%. Ginkgolide B, at 3-30 µM, had no effect on the emission ratio, whereas at 100, 300, and 1000 µM, it decreased the ratio by 33%, 37%, and 48%, respectively. Comparatively, SR12813, at 0.01 nM to 100 µM, decreased the TR-FRET emission ratio by 27% to 97%.
TR-FRET Competitive Ligand Binding of Individual Ginkgolides to the
Effect of Individual Ginkgolides on SRC-1 Coactivator Recruitment to hPXR in
Cultured HepG2 Cells. To determine whether there is ligand selectivity in the effect of the individual ginkgolides on SRC-1 recruitment, a mammalian two-hybrid assay conducted in HepG2 cells transfected with pFR-luc, pM-hSRC1-RID, and either pVP16-hPXR-LBD or pVP16 (empty vector). In HepG2 cells co-transfected with both pM-hSRC1-RID and pVP16-hPXR-LBD, ginkgolide A (100 µM) and ginkgolide B (100 µM) increased the luciferase reporter activity by 10-and 13-fold, respectively (Fig. 6 ). In contrast, ginkgolide C and ginkgolide J had no effect. As expected, phenobarbital (1000 µM; positive control) , SR12813
(10 µM; positive control) , and rifampicin (10 µM; positive control) increased the reporter activity, whereas PCN (10 µM; negative control) ) had no effect. Control analysis also indicated a lack of increase in the reporter activity by each of the treatment groups in cells not transfected with the pVP16-hPXR-LBD expression plasmid.
Effect of Individual Ginkgolides on LDH Release in LS180 and HepG2 Cells.
Ginkgolide J did not affect hPXR target gene expression or PXR activity in various cell-based assays (Fig. 2, 3 , 4, and 6). However, it is not known whether cellular necrosis was associated with the concentrations of this ginkgolide used in those experiments. Therefore, we determined 
Discussion
A major finding in the present study is that ginkgolide A, ginkgolide B, and ginkgolide C activate hPXR, but not hGR, hCAR-WT, hCAR-SV23, hCAR-SV24, or hCAR-SV25. This receptor selectivity is similar to that of rifampicin, which also activates hPXR (Lehmann et al., 1998) , but not hGR [ (Herr et al., 2000) and present study] or hCAR-WT .
The receptor selectivity of ginkgolides may be related to differences in the size and flexibility of the ligand-binding domain of these receptors. hPXR (~1200 Å 3 ) (Timsit and Negishi, 2007 ) has a larger and more flexible ligand-binding domain, when compared with hGR (~600 Å 3 in each subunit) (Veleiro et al., 2010) and hCAR-WT (~675 Å 3 ) (Timsit and Negishi, 2007) . This allows hPXR to accommodate a diverse group of ligands of different shapes and sizes. Our detailed concentration-response experiments indicate that ginkgolide A and ginkgolide B activated hPXR to a similar extent as rifampicin, whereas ginkgolide C was a weak activator and ginkgolide J had no effect. However, ginkgolide A, ginkgolide B, and ginkgolide C were less potent than rifampicin. Among the naturally-occurring chemicals, hyperforin, forskolin, and cryptotanshinone are potent hPXR activators with EC 50 in the submicromolar range (Chang, 2009 ). By comparison, ginkgolide A was less potent (EC 50 = 16.2 μ M), but similarly efficacious (E max = 11.5 fold) as hyperforin (EC 50 = 0.02-0.2 μ M; E max = 6-12 fold) (Chang, 2009 ). Overall, we have identified specific ginkgolides as selective, naturally-occurring ligands of hPXR, but not of hGR or hCAR-WT.
Despite the small structural differences among the four ginkgolides investigated, only Although ginkgolide C increased hPXR-mediated luciferase reporter activity (Satsu et al., 2008 and present study), it did not transactivate or bind to the ligand-binding domain of hPXR, as assessed by the assays employed in the present study. The functional differences among the four ginkgolides may be explained by their structural differences. Ginkgolide A, ginkgolide B, ginkgolide C, and ginkgolide J differ structurally in their substitutions at the C 1 and C 7 positions (Fig. 1) . Whereas the OH-group at the C 1 position does not affect the activation of hPXR because ginkgolide A and ginkgolide B activate hPXR to similar extent (Satsu et al., 2008 and present study) , the presence of an OH-group at the C 7 position appears to be unfavorable for hPXR activation. The latter is illustrated by our finding that hPXR activation is completely abolished when a H-group at the C 7 position of ginkgolide A is changed to an OH-group in ginkgolide J. Likewise, with an additional OH-group at the C 1 position, a change from a Hgroup at the C 7 position of ginkgolide B to an OH-group in ginkgolide C also substantially decreases hPXR activation. Overall, the type of substituents at the C 7 position of these diterpenes appears to be a determinant in hPXR activation. Although the ligand-binding domain of hPXR can accommodate ligands with diverse structures (Timsit and Negishi, 2007) , our present study with the individual ginkgolides indicates that a slight modification in chemical structure can lead to drastic changes in the functionality of this receptor. Interestingly, in contrast to the structure-activity relationship in hPXR agonism, the OH group at the C 1 position of ginkgolides is necessary for glycine receptor antagonism (Ivic et al., 2003) . Overall, our novel findings provide mechanistic information on hPXR activation by individual ginkgolides and show that subtle differences in chemical structure can confer pronounced differences in the functionality of hPXR.
This article has not been copyedited and formatted. The final version may differ from this version. These features of ginkgolides fit the proposed pharmacophore of hPXR ligands, which includes a molecular weight > 300 daltons, an ability to form hydrophobic interactions (e.g. aromatic π -π interactions), and the presence of hydrogen bond acceptors (one or two) and hydrogen bond donors (Xiao et al., 2011) . Although molecular docking analysis predict that ginkgolide J, which is bioactive (Vitolo et al., 2009) , binds very weakly to the ligand-binding domain of the receptor, it does not activate hPXR, as shown in the various assays conducted in the present study.
However, it is possible that ginkgolide J is capable of acting as an antagonist of hPXR, but future studies are needed to address this issue.
Pronounced species differences in the activation of hPXR and rPXR have been reported.
For example, rifampicin activates hPXR but not rPXR, whereas PCN activates rPXR but not hPXR . Our novel findings indicate that the pattern of activation of hPXR and rPXR by the four ginkgolides were qualitatively similar, although ginkgolide B activated hPXR to a somewhat greater extent than rPXR. In general, these findings indicate that species differences in the structure of the ligand-binding domains of hPXR and rPXR are not a critical , and site-directed mutagenesis studies identified that Leu-308 in hPXR accounts for the species differences in hPXR and rPXR activation by rifampicin, paclitaxel, hyperforin, nifedipine, and PCN (Tirona et al., 2004) . However, according to our molecular docking data, Leu-308 is not involved in the binding of the individual ginkgolides to the ligand-binding domain of hPXR. Therefore, this may explain the observed lack of pronounced species differences in hPXR and rPXR activation by these chemicals. Molecular modeling also predicted that several other amino acid residues in hPXR (Table 2 ) interact with the individual ginkgolides. Given that these ginkgolides did not show pronounced species-dependent activation of hPXR and rPXR in the reporter gene assays, it is proposed that those amino acid residues are not critical determinants of species-dependent activation of these receptors.
In conclusion, the individual ginkgolides regulate the function of nuclear receptors in a receptor-selective and chemical-dependent manner. None of the ginkgolides activates hGR or hCAR, whereas ginkgolide A, ginkgolide B, and ginkgolide C, but not ginkgolide J, activate hPXR and rPXR. Among the ginkgolides investigated, only ginkgolide A and ginkgolide B exhibit hPXR agonism. Overall, our study provides mechanistic insight into the structureactivity relationship in hPXR activation by ginkgolides. This class of naturally-occurring chemicals may have the potential for PXR-based drug development because this receptor has been proposed as a therapeutic target for various disease conditions (Kakizaki et al., 2011) .
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